Izrael - angličtina - Ministry of Health

novartis israel ltd - entacapone - film coated tablets - entacapone 200 mg - entacapone - entacapone - entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson`s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - benzatropine mesilate, quantity: 1 mg/ml - injection - excipient ingredients: sodium chloride; water for injections - benzatropine injection is recommended for all forms of parkinsonism - including arteriosclerotic, post-encephalitic, idiopathic, as well as drug induced extrapyramidal disorders (except tardive dyskinesia). it can be effective at any stage of the disease, even when a patient has become bedridden. benzatropine injection often is helpful in patients who have become unresponsive to other agents. benzatropine injection is a powerful antichlolinergic agent which is mainly effective in relieving tremor and rigidity. therapy is directed toward control of disturbing symptoms to permit the patient maximum integration of function with minimum discomfort. in non-drug-induced parkinsonism, partial control of symptoms is usually achieved.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg - tablet, modified release - excipient ingredients: indigo carmine; hypromellose; hyprolose; allura red ac; magnesium stearate - idiopathic parkinsonism, where standard formulations containing levodopa/carbidopa have produced inadequate control. experience is limited with sinemet cr in patients who have not been treated with levodopa before.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 125 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 75 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 200 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 150 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 100 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 50 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - benzatropine mesilate, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate - indicated for the treatment of all forms of parkinsonism. the treatment of extrapyramidal reactions (except tardive dyskinesia [see contraindications and precautions]) due to neuroleptic drugs.